Comparative Pharmacology
Head-to-head clinical analysis: OXYCODONE 2 5 APAP 500 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCODONE 2 5 APAP 500 versus QDOLO.
OXYCODONE 2.5/APAP 500 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1-2 tablets (oxycodone 2.5-5 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP 4000 mg/day (consider lower APAP limit per institutional guidelines).
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Oxycodone: 3.5-5.5 hours in healthy adults; steady state reached within 24 hours. Acetaminophen: 2-3 hours; prolonged in hepatic impairment.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Oxycodone: primarily renal (87% as metabolites, 10% unchanged). Acetaminophen: primarily renal (90-100% as glucuronide and sulfate conjugates, 2-5% unchanged). Fecal elimination <10%
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist